Bruker: Q2 Earnings Insights

Shares of Bruker BRKR moved higher by 0.06% in after-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share fell 36.36% year over year to $0.21, which beat the estimate of $0.06.

Revenue of $424,600,000 declined by 13.38% from the same period last year, which beat the estimate of $390,920,000.

Guidance

Earnings guidance hasn't been issued by the company for now.

Bruker hasn't issued any revenue guidance for the time being.

Conference Call Details

Date: Aug 03, 2020

Time: 04:30 PM

ET Webcast URL: https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer=https%3A%2F%2Fir.bruker.com%2Fevents-and-presentations%2Fdefault.aspx&eventid=2405685&sessionid=1&key=BEAAF9A4978E1F5180844F6D9CE668EB&regTag=&sourcepage=register

Recent Stock Performance

Company's 52-week high was at $54.49

Company's 52-week low was at $30.78

Price action over last quarter: Up 16.03%

Company Profile

Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, pharmaceutical, and biotechnology industries. The vast majority of revenue comes from the scientific instruments segment, which develops tools based on magnetic resonance, mass spectrometry, and X-ray technologies. The remainder of the firm's business comes from the energy and superconductor technology segment, which manufactures superconducting materials primarily used in magnetic resonance imaging, nuclear magnetic resonance, and fusion energy research. The largest proportion of Bruker's revenue comes from Europe, though the firm also has a significant presence in the United States and Asia.